Skip to Content
Biotechnology and health

A new personal genome test is free, but only if you bare all about your life

November 15, 2018

A startup company says it will give people free genome reports if they’re willing to answer detailed questions about their health, drinking habits, and more, according to Xconomy

The deal: Nebula Genomics plans to create rough-and-ready maps of people’s genomes, similar to tests from companies like 23andMe. It costs $99 if you want to pay up front, but you can also earn credits toward a free test if you answer some detailed questions about yourself. 

The catch: The company wants to sell information about you to drug companies. Cofounder Kamal Obbad says that will only happen if you give permission. You can pick and choose what studies to participate in, he says. 

The big picture: By amassing huge troves of health and DNA data on hundreds of thousands of people, scientists are trying to zero in on the genetic predictors of disease. By giving away a DNA test, Nebula is hoping to quickly get into the game too. 

“We are figuring out the business model,” Obbad says. “But we’re making a bet that genetics is going to take off.”

What you learn: Nebula will create a picture of your genome that’s quite broad but relatively low in accuracy, known as a “1x genome.” That means each of the billions of DNA letters is read out just once on average (whereas more accurate “30x” sequencing can remove errors).

It’s therefore not a health test, Obbad says: “If you want health or medical information, this is not the solution for you.” 

Instead, the company will tell users about their ancestry and various traits linked to athletic performance, height, and eye and hair color, as do companies like 23andMe and Ancestry.com. 

Personality traits: Obbad says Nebula will also report on what your DNA says about personality traits such as happiness or risk-taking tendencies. It even claims to be able to make predictions about educational attainment. The meaning of such personality reports or IQ predictions remain controversial, to say the least.

Deep Dive

Biotechnology and health

What to know about this autumn’s covid vaccines

New variants will pose a challenge, but early signs suggest the shots will still boost antibody responses.

A biotech company says it put dopamine-making cells into people’s brains

The experiment to treat Parkinson’s is a critical early test of stem cells’ potential to tackle serious disease.

Tiny faux organs could crack the mystery of menstruation

Researchers are using organoids to unlock one of the human body’s most mysterious—and miraculous—processes.

How AI can help us understand how cells work—and help cure diseases

A virtual cell modeling system, powered by AI, will lead to breakthroughs in our understanding of diseases, argue the cofounders of the Chan Zuckerberg Initiative.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.